What question did this study set out to answer?

This research investigates the effectiveness of oral azacitidine as maintenance therapy after allogeneic stem cell transplant in patients with myeloid malignancies.

December 8, 2025Blood

Oral azacitidine as maintenance therapy post allogeneic stem cell transplant in patients with myeloid malignancies

View Full Paper

Ask AI

Bookmark

Authors

MNMichelle NwachukwuUniversity of Illinois Chicago JRJeremy RamdialThe University of Texas MD Anderson Cancer Center CRCaitlin R. RauschThe University of Texas MD Anderson Cancer Center

Discussion

Member takes

Implication

Study finds oral azacitidine improves survival rates in myeloid malignancies post-transplant, suggesting further exploration needed.

Key Points

This research investigates the effectiveness of oral azacitidine as maintenance therapy after allogeneic stem cell transplant in patients with myeloid malignancies.
Patients with myeloid disorders received daily oral azacitidine post-SCT.
Treatment continued after engraftment and resolution of graft-versus-host disease.
Measurable residual disease was assessed by flow cytometry.
Median overall survival was 27.85 months; median relapse-free survival was 8.5 months.
Gastrointestinal side effects were the most common reason for treatment discontinuation.
Out of evaluable patients, half remained measurable residual disease negative after treatment.

Cite This Study

Nwachukwu et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d33b https://doi.org/10.1182/blood-2025-6975

View Full Paper

Ask AI

Bookmark

Oral azacitidine as maintenance therapy post allogeneic stem cell transplant in patients with myeloid malignancies

Discussion

Member takes

Implication

Key Points

Cite This Study

Oral azacitidine as maintenance therapy post allogeneic stem cell transplant in patients with myeloid malignancies

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider